CSIMarket
 


Pluri Inc   (PLUR)
Other Ticker:  
 

Pluri Inc 's Tangible Leverage Ratio

PLUR's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to net new borrowings of 5.13%, Tangible Leverage Ratio fell to 4.8, a new company high.

Within Biotechnology & Pharmaceuticals industry in the second quarter 2023, 10 other companies have achieved lower Tangible Leverage Ratio than Pluri Inc in the II Quarter 2023. While Tangible Leverage Ratio total ranking has improved so far in the second quarter 2023 to 699, from total ranking in the first quarter 2023 at 2856 .

Explain Tangible Leverage Ratio?
What is PLUR Market Share?
What are PLUR´s Total Liabilities?


PLUR Tangible Leverage Ratio (Dec 31 2023)
II. Quarter
(Sep 30 2023)
I. Quarter
(Jun 30 2023)
IV. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
II. Quarter
Y / Y Tangible Equity Change -73.5 % -58.97 % -52.46 % -47.98 % -37.33 %
Y / Y Total Liabilities Change 4.15 % 3.25 % 0.55 % -7.74 % -9.59 %
Tangible Leverage Ratio MRQ 4.8 2.74 2.07 1.49 1.22
PLUR's Total Ranking # 699 # 2856 # 2713 # 1554 # 450
Seq. Tangible Equity Change -40.05 % -27.86 % -26.73 % -16.36 % -7.19 %
Seq. Total Liabilities Change 5.13 % -4.68 % 1.75 % 2.14 % 4.23 %



Tangible Leverage Ratio second quarter 2023 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 11
Healthcare Sector # 92
Overall Market # 699


Tangible Leverage Ratio Statistics
High Average Low
4.8 0.57 0.13
(Dec 31 2023)   (Sep 30 2012)




Financial Statements
Pluri Inc 's Tangible Equity $ 7 Millions Visit PLUR's Balance sheet
Pluri Inc 's Total Liabilities $ 32 Millions Visit PLUR's Balance sheet
Source of PLUR's Sales Visit PLUR's Sales by Geography


Cumulative Pluri Inc 's Tangible Leverage Ratio

PLUR's Tangible Leverage Ratio for the trailling 12 Months

PLUR Tangible Leverage Ratio

(Dec 31 2023)
II. Quarter
(Sep 30 2023)
I. Quarter
(Jun 30 2023)
IV. Quarter
(Mar 31 2023)
III. Quarter
(Dec 31 2022)
II. Quarter
Y / Y Tangible Equity TTM Growth -73.5 % -58.97 % -52.46 % -47.98 % -37.33 %
Y / Y Total Liabilities TTM Growth 4.15 % 3.25 % 0.55 % -7.74 % -9.59 %
Tangible Leverage Ratio TTM 2.32 1.71 1.39 1.17 1.01
Total Ranking TTM # 1840 # 2437 # 2365 # 2233 # 2360
Seq. Tangible Equity TTM Growth -40.05 % -27.86 % -26.73 % -16.36 % -7.19 %
Seq. Total Liabilities TTM Growth 5.13 % -4.68 % 1.75 % 2.14 % 4.23 %


On the trailing twelve months basis Due to the net new borrowings of 5.13% during the trailing twelve months finishing in the II Quarter 2023, cumulativeTangible Leverage Ratio improved to 2.32, above the Pluri Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry 3, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Pluri Inc . While Tangible Leverage Ratio total ranking has improved so far to 30, from total ranking in previous 12 month period at 2775.

Explain Tangible Leverage Ratio?
What is PLUR Market Share?
What are PLUR´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 4
Healthcare Sector # 24
Within the Market # 699


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
1.75 0.73 0.11
(Dec 31 2023)   (Jun 30 2021)




Companies with similar Tangible Leverage Ratio in the quarter ending Dec 31 2023, within Biotechnology & Pharmaceuticals Industry Tangible Leverage RatioDec 31 2023 MRQ Total LiabilitiesDec 31 2023 MRQ Tangible Equity
Enzon Pharmaceuticals inc   12.61 $ 44.197  Millions$ 3.505  Millions
Adaptimmune Therapeutics Plc  6.20 $ 243.103  Millions$ 39.183  Millions
Inhibrx Inc   6.00 $ 261.217  Millions$ 43.503  Millions
Curis Inc   5.27 $ 56.307  Millions$ 10.688  Millions
Pluri Inc   4.80 $ 31.762  Millions$ 6.617  Millions
Valneva Se  2.59 $ 371.633  Millions$ 143.637  Millions
Qiagen N v   2.10 $ 1,692.857  Millions$ 805.211  Millions
Coeptis Therapeutics Holdings Inc   2.08 $ 3.658  Millions$ 1.760  Millions
Cyclo Therapeutics Inc   1.57 $ 7.457  Millions$ 4.757  Millions
Pharmacyte Biotech Inc   1.44 $ 39.984  Millions$ 27.826  Millions
Adma Biologics Inc   1.38 $ 181.282  Millions$ 131.177  Millions
Protalix Biotherapeutics inc   1.38 $ 46.244  Millions$ 33.569  Millions
Meiragtx Holdings Plc  1.38 $ 188.567  Millions$ 137.059  Millions
Bio techne Corp  1.35 $ 582.231  Millions$ 432.872  Millions
Cel sci Corporation  1.29 $ 16.060  Millions$ 12.462  Millions
Sangamo Therapeutics Inc   0.99 $ 82.433  Millions$ 82.887  Millions

Date modified: 2024-02-13T09:14:03+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com